Malcolm Brenner, MD, PhD

Full Affiliate Member, Research Institute
Houston Methodist


Dr. Brenner completed his postdoctoral training in 1981 and joined the Clinical Research Centre of Northwick Park Hospital in London, England as a MRC Clinical Scientist and Honorary Senior Registrar. He also began lecturing in Haematology at the Royal Free Hospital and Hospital for Sick Children, also in London.

Dr. Brenner joined the faculty at the University of Tennessee in Memphis as a Professor in the Departments of Pediatrics and Medicine in 1990. He also became the Director of the Bone Marrow Transplant Division of the St. Jude Children's Research Hospital that same year. He later directed the Cell and Gene Therapy Program at St. Jude's from 1994 until 1997, when he assumed his current positions at the Baylor College of Medicine.

Description of Research

Dr. Brenner's research focuses on gene transfer to stem cells and to effector cells of the immune system. His research group was one of the first to use gene transfer in human subjects, establishing the feasibility of tracking human stem cells and their progeny in subjects with cancer. Dr. Brenner also develops tumor vaccines for pediatric and hematological malignancies, using genetic modification with retroviral and adenoviral vectors.

Areas Of Expertise

Stem cells Gene therapy Cell therapy Vectors
Education & Training

PhD, Cambridge University

Enhancing the potency and specificity of engineered T cells for cancer treatment
Sukumaran, S, Watanabe, N, Bajgain, P, Raja, K, Mohammed, S, Fisher, WE, Brenner, MK, Leen, AM & Vera, JF 2018, Cancer Discovery, vol. 8, no. 8, pp. 972-987. DOI: 10.1158/2159-8290.CD-17-1298

CAR T cell therapy for breast cancer: Harnessing the tumor milieu to drive T cell activation
Bajgain, P, Tawinwung, S, DElia, L, Sukumaran, S, Watanabe, N, Hoyos, V, Lulla, P, Brenner, MK, Leen, AM & Vera, JF 2018, Journal for ImmunoTherapy of Cancer, vol. 6, no. 1, 34. DOI: 10.1186/s40425-018-0347-5

Tumor-specific t-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma
Bollard, CM, Tripic, T, Cruz, CR, Dotti, G, Gottschalk, S, Torrano, V, Dakhova, O, Carrum, G, Ramos, CA, Liu, H, Wu, MF, Marcogliese, AN, Barese, C, Zu, Y, Lee, DY, O’Connor, O, Gee, AP, Brenner, MK, Heslop, HE & Rooney, CM 2018, Journal of Clinical Oncology, vol. 36, no. 11, pp. 1128-1139. DOI: 10.1200/JCO.2017.74.3179

Onward and upward for immuno-oncology
Brenner, MK 2018, Chinese Clinical Oncology, vol. 7, no. 2, 18. DOI: 10.21037/cco.2018.01.04

Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy
Heslop, HE & Brenner, MK 2018, Molecular Therapy, vol. 26, no. 1, pp. 1-2. DOI: 10.1016/j.ymthe.2017.12.004

Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives—A Single-Center Experience, 2008 to 2016
Yanir, AD, Martinez, CA, Sasa, G, Leung, K, Gottschalk, S, Omer, B, Ahmed, N, Hegde, M, Eunji, J, Liu, H, Heslop, HE, Brenner, MK, Krance, RA & Naik, S 2018, Biology of Blood and Marrow Transplantation. DOI: 10.1016/j.bbmt.2018.03.001

High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease
Yanir, AD, Hanson, IC, Shearer, WT, Noroski, LM, Forbes, LR, Seeborg, FO, Nicholas, S, Chinn, I, Orange, JS, Rider, NL, Leung, KS, Naik, S, Carrum, G, Sasa, G, Hegde, M, Omer, BA, Ahmed, N, Allen, CE, Khaled, Y, Wu, MF, Liu, H, Gottschalk, SM, Heslop, HE, Brenner, MK, Krance, RA & Martinez, CA 2018, Biology of Blood and Marrow Transplantation. DOI: 10.1016/j.bbmt.2018.03.029

Reversible transgene expression reduces fratricide and permits 4-1BB Costimulation of CAR T cells directed to T-cell malignancies
Mamonkin, M, Mukherjee, M, Srinivasan, M, Sharma, S, Gomes-Silva, D, Mo, F, Krenciute, G, Orange, JS & Brenner, MK 2018, Cancer Immunology Research, vol. 6, no. 1, pp. 47-58. DOI: 10.1158/2326-6066.CIR-17-0126

Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome
Ngwube, A, Hanson, IC, Orange, J, Rider, NL, Seeborg, F, Shearer, W, Noroski, L, Nicholas, S, Forbes, L, Leung, K, Sasa, G, Naik, S, Hegde, M, Omer, B, Ahmed, N, Allen, C, Gottschalk, S, Wu, MF, Liu, H, Brenner, M, Heslop, H, Krance, R & Martinez, C 2018, Biology of Blood and Marrow Transplantation. DOI: 10.1016/j.bbmt.2017.11.019

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas
Ramos, CA, Rouce, R, Robertson, CS, Reyna, A, Narala, N, Vyas, G, Mehta, B, Zhang, H, Dakhova, O, Carrum, G, Kamble, RT, Gee, AP, Mei, Z, Wu, MF, Liu, H, Grilley, B, Rooney, CM, Heslop, HE, Brenner, MK, Savoldo, B & Dotti, G 2018, Molecular Therapy. DOI: 10.1016/j.ymthe.2018.09.009

C-MPL provides tumor-Targeted T-cell receptor-Transgenic T cells with costimulation and cytokine signals
Nishimura, CD, Brenner, DA, Mukherjee, M, Hirsch, RA, Ott, L, Wu, MF, Liu, H, Dakhova, O, Orange, JS, Brenner, MK, Lin, CY & Arber, C 2017, Blood, vol. 130, no. 25, pp. 2739-2749. DOI: 10.1182/blood-2017-02-769463

Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer
Rosewell Shaw, A, Porter, CE, Watanabe, N, Tanoue, K, Sikora, A, Gottschalk, S, Brenner, MK & Suzuki, M 2017, Molecular Therapy, vol. 25, no. 11, pp. 2440-2451. DOI: 10.1016/j.ymthe.2017.09.010

Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation
Tzannou, I, Papadopoulou, A, Naik, S, Leung, K, Martinez, CA, Ramos, CA, Carrum, G, Sasa, G, Lulla, P, Watanabe, A, Kuvalekar, M, Gee, AP, Wu, MF, Liu, H, Grilley, BJ, Krance, RA, Gottschalk, S, Brenner, MK, Rooney, CM, Heslop, HE, Leen, AM & Omer, B 2017, Journal of Clinical Oncology, vol. 35, no. 31, pp. 3547-3557. DOI: 10.1200/JCO.2017.73.0655

Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells
Shum, T, Omer, B, Tashiro, H, Kruse, RL, Wagner, DL, Parikh, K, Yi, Z, Sauer, T, Liu, D, Parihar, R, Castillo, P, Liu, H, Brenner, MK, Metelitsa, LS, Gottschalk, S & Rooney, CM 2017, Cancer Discovery, vol. 7, no. 11, pp. 1238-1247. DOI: 10.1158/2159-8290.CD-17-0538

Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent
Gomes-Silva, D, Mukherjee, M, Srinivasan, M, Krenciute, G, Dakhova, O, Zheng, Y, Cabral, JMS, Rooney, CM, Orange, JS, Brenner, MK & Mamonkin, M 2017, Cell Reports, vol. 21, no. 1, pp. 17-26. DOI: 10.1016/j.celrep.2017.09.015

Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1
Tashiro, H, Sauer, T, Shum, T, Parikh, K, Mamonkin, M, Omer, B, Rouce, RH, Lulla, P, Rooney, CM, Gottschalk, S & Brenner, MK 2017, Molecular Therapy, vol. 25, no. 9, pp. 2202-2213. DOI: 10.1016/j.ymthe.2017.05.024

Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Ramos, CA, Ballard, B, Zhang, H, Dakhova, O, Gee, AP, Mei, Z, Bilgi, M, Wu, MF, Liu, H, Grilley, B, Bollard, CM, Chang, BH, Rooney, CM, Brenner, MK, Heslop, HE, Dotti, G & Savoldo, B 2017, Journal of Clinical Investigation, vol. 127, no. 9, pp. 3462-3471. DOI: 10.1172/JCI94306

HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: A phase 1 dose-escalation trial
Ahmed, N, Brawley, V, Hegde, M, Bielamowicz, K, Kalra, M, Landi, D, Robertson, C, Gray, TL, Diouf, O, Wakefield, A, Ghazi, A, Gerken, C, Yi, Z, Ashoori, A, Wu, MF, Liu, H, Rooney, C, Dotti, G, Gee, A, Su, J, Kew, Y, Baskin, D, Zhang, YJ, New, P, Grilley, B, Stojakovic, M, Hicks, J, Powell, SZ, Brenner, MK, Heslop, HE, Grossman, R, Wels, WS & Gottschalk, S 2017, JAMA Oncology, vol. 3, no. 8, pp. 1094-1101. DOI: 10.1001/jamaoncol.2017.0184

CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
Gomes-Silva, D, Srinivasan, M, Sharma, S, Lee, CM, Wagner, DL, Davis, TH, Rouce, RH, Bao, G, Brenner, MK & Mamonkin, M 2017, Blood, vol. 130, no. 3, pp. 285-296. DOI: 10.1182/blood-2017-01-761320

Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of Chimeric antigen receptor t cells in solid tumors
Tanoue, K, Shaw, AR, Watanabe, N, Porter, C, Rana, B, Gottschalk, S, Brenner, M & Suzuki, M 2017, Cancer Research, vol. 77, no. 8, pp. 2040-2051. DOI: 10.1158/0008-5472.CAN-16-1577